Ainnova utilizes artificial intelligence to analyze retinal images for the rapid detection of diabetic retinopathy and other retinal diseases during fundus eye tests. This technology enables early diagnosis and intervention, significantly reducing the risk of blindness and improving overall eye health for patients, particularly those with diabetes.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diabetic retinopathy and other retinal diseases often go undetected until vision loss occurs, particularly in patients with limited access to specialist care. Traditional screening methods require trained professionals and can be time-consuming, leading to delayed diagnoses and increased risk of irreversible damage.
Solution
Ainnova has developed Vision AI, a web platform that uses artificial intelligence to rapidly analyze retinal images for early detection of diabetic retinopathy and other retinal diseases during fundus eye tests. The platform identifies these conditions with high accuracy within seconds, enabling early intervention and reducing the risk of blindness. By providing a streamlined and cost-efficient process, Vision AI enhances patient satisfaction and boosts the reputation of medical centers.
Target Audience
The primary target audience includes primary care providers, medical specialists, and hospitals seeking to improve early detection and management of retinal diseases, particularly in diabetic patients.
Features
- AI-powered analysis of fundus images for rapid detection of retinal diseases
- High accuracy in identifying diabetic retinopathy and other conditions
- Web-based platform accessible to primary care providers and specialists
- Streamlined workflow for efficient screening and diagnosis
- Automated reporting and integration with existing healthcare systems